Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 600

[192] Cleland JL, Johnson OL, Putney S, Jones AJS. Recombinant human growth hormone
poly(lactic- co -glycolic acid) microsphere formulation development. Adv Drug Delivery
Rev 1997;28:71-84.
[193] Tsai TM, Mehta RC, DeLuca PP. Adsorption of peptides to poly (D,L-lactide- co -gly-
colide). 1. Effect of physical factors on the adsorption. Int J Pharm 1996;127:31-42.
[194] Hayashi Y, Yoshioka S, Aso Y, Po ALW, Terao T. Entrapment of proteins in poly
(L-lactide) microspheres using reversed micelle solvent evaporation. Pharm Res 1994;11:
337-40.
[195] Sanchez A, Vilajato JL, Alonso MJ. Development of biodegradable microspheres and
nanospheres for the controlled release of cyclosporin-A. Int J Pharm 1993;99:263-73.
[196] Yamakawa I, Tsushima Y, Machida R, Watanabe S. Preparation of neurotensin ana-
logue-containing poly(DL-lactic acid) microspheres formed by oil-in-water solvent
evaporation. J Pharm Sci 1992;81:899-903.
[197] Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, et al. PEGylated PLGA nanoparticles
as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release
2001;71:203-11.
[198] Sakakibara Y, Nishimura K, Tambara K, Yamamoto M, Lu F, Tabata Y, et al. Pre-
vascularization with gelatin microspheres containing basic fibroblast growth factor enhances
the benefits of cardiomyocyte transplantation. J Thorac Cardiovasc Surg 2002;124:50-56.
[199] Weiner AL. Lipid-based vehicles for peptide and protein drugs: part II: manufacturing
variables. Bio Pharm Int 1990;3:16-21.
[200] Hsieh DS, Smith N, Chien YW. Subcutaneous controlled delivery of estradiol by
Compudose implants: in vitro and in vivo evaluations. Drug Dev Ind Pharm 1987;13:
2651-66.
[201] Kirkpatrick DK, Trachtenberg LS, Mangino PD, Von Fraunhofer JA, Seligson D.
In vitro characteristics of tobramycin-PMMA beads: compressive strength and leaching.
Orthopedics 1985;8:1130-3.
[202] Hsieh DS, Rhine WD, Langer R. Zero-order controlled-release matrice for micro- and
macromolecules. J Pharm Sci 1983;72:17-22.
[203] Al-Tahami K, Singh J. Smart polymer based delivery systems for peptides and proteins.
Recent Pat Drug Deliv Formul 2007;1:65-71.
[204] Chaubal M. Excipient update: polylactides/glycolides—excipient for injectable drug deliv-
ery and beyond. http:// www.drugdel.com/ExcipientUpdate1.pdf . Accessed May 2010.
[205] Edman P, Sjoholm I. Prolongation of effects of asparaginase by implantation in poly-
acrylamide in rats. J Pharm Sci 1981;70:684-5.
[206] Kruisbrink J, Boer GJ. The use of (3H) vasopressin for in-vivo studies of controlled
delivery from an accurel/collodion device in the Brattleboro rat. J Pharm Pharmacol
1986;38:893-97.
[207] Kruisbrink J, Boer GJ. Controlled long-term release of small peptide hormones using a
new microporous polypropylene polymer: its application for vasopressin in the Brattleboro
rat and potential perinatal use. J Pharm Sci 1984;73:1713-18.
[208] Sanders LM, Kell BA, McRae GI, Whitehead GW. Prolonged controlled-release of
nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable poly-
meric implants: influence of composition and molecular weight of polymer. J Pharm
Sci 1986;75:356-60.
[209] Stevenson CL. Formulation of leuprolide at high concentration for delivery from a one
year duration implant. In: McNally EJ, Hastedt JE, editors. Protein formulation and
delivery, vol. 175. New York, NY: Drugs And The Pharmaceutical Sciences Series,
Informa Healthcare Inc.; 2007:154.